Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 4
2015 3
2016 4
2017 2
2018 7
2019 9
2020 11
2021 7
2022 9
2023 5

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Results by year

Filters applied: . Clear all
Page 1
A Narrative Review on the Collection and Use of Electronic Patient-Reported Outcomes in Cancer Survivorship Care with Emphasis on Symptom Monitoring.
van den Hurk CJG, Mols F, Eicher M, Chan RJ, Becker A, Geleijnse G, Walraven I, Coolbrandt A, Lustberg M, Velikova G, Charalambous A, Koczwara B, Howell D, Basch EM, van de Poll-Franse LV. van den Hurk CJG, et al. Among authors: walraven i. Curr Oncol. 2022 Jun 17;29(6):4370-4385. doi: 10.3390/curroncol29060349. Curr Oncol. 2022. PMID: 35735458 Free PMC article. Review.
In Regard to Redmond et al.
Belderbos J, Schagen S, Walraven I, Deprez S, de Ruiter M, De Ruysscher D, Le Pechoux C. Belderbos J, et al. Among authors: walraven i. Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):238-239. doi: 10.1016/j.ijrobp.2017.05.012. Epub 2017 Aug 7. Int J Radiat Oncol Biol Phys. 2017. PMID: 28816152 No abstract available.
Measuring chronic myeloid leukaemia TKI-related toxic effects in the real world: a systematic review and critical assessment of content validity of patient-reported outcome measures.
Smit Y, Metsemakers SJJPM, Janssen JJWM, Posthuma EFM, Walraven I, Hermens RPMG, Blijlevens NMA. Smit Y, et al. Among authors: walraven i. Lancet Haematol. 2023 Oct;10(10):e849-e859. doi: 10.1016/S2352-3026(23)00173-4. Epub 2023 Aug 18. Lancet Haematol. 2023. PMID: 37604177 Review.
Adverse event development in clinical oncology trials.
Walraven I, Aaronson N, Sonke JJ, Verheij M, Belderbos J. Walraven I, et al. Lancet Oncol. 2016 Jul;17(7):e263. doi: 10.1016/S1470-2045(16)30197-8. Lancet Oncol. 2016. PMID: 27396639 No abstract available.
Development of an updated, standardized, patient-centered outcome set for lung cancer.
de Rooij BH, van den Hurk C, Smaardijk V, Fernandez-Ortega P, Navarro-Martin A, Barberio L, Guckenberger M, Schmid S, Walraven I, Vallow S, Kotsi C, Preusser M, Mosor E, Klok JM, Becker A, Milani A, Ninov L, van de Poll-Franse LV. de Rooij BH, et al. Among authors: walraven i. Lung Cancer. 2022 Nov;173:5-13. doi: 10.1016/j.lungcan.2022.08.021. Epub 2022 Sep 5. Lung Cancer. 2022. PMID: 36103777 Free article.
Knowledge-Based Assessment of Focal Dose Escalation Treatment Plans in Prostate Cancer.
van Schie MA, Janssen TM, Eekhout D, Walraven I, Pos FJ, de Ruiter P, Kotte ANTJ, Monninkhof EM, Kerkmeijer LGW, Draulans C, de Roover R, Haustermans K, Kunze-Busch M, Smeenk RJ, van der Heide UA. van Schie MA, et al. Among authors: walraven i. Int J Radiat Oncol Biol Phys. 2020 Nov 15;108(4):1055-1062. doi: 10.1016/j.ijrobp.2020.06.072. Epub 2020 Jul 3. Int J Radiat Oncol Biol Phys. 2020. PMID: 32629078 Clinical Trial.
54 results